Novo Nordisk A/S (NVO)
45.59
+0.26
(+0.57%)
USD |
NYSE |
Sep 01, 09:59
Novo Nordisk Net Income (TTM) : 18.19B for June 30, 2026
Net Income (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 18.19B |
| March 31, 2026 | 18.95B |
| December 31, 2025 | 15.45B |
| September 30, 2025 | 15.29B |
| June 30, 2025 | 16.18B |
| March 31, 2025 | 15.05B |
| December 31, 2024 | 14.65B |
| September 30, 2024 | 13.78B |
| June 30, 2024 | 13.04B |
| March 31, 2024 | 12.98B |
| December 31, 2023 | 12.14B |
| September 30, 2023 | 10.84B |
| June 30, 2023 | 9.508B |
| March 31, 2023 | 8.575B |
| December 31, 2022 | 7.861B |
| September 30, 2022 | 7.671B |
| June 30, 2022 | 7.642B |
| March 31, 2022 | 7.703B |
| December 31, 2021 | 7.605B |
| September 30, 2021 | 7.423B |
| June 30, 2021 | 7.119B |
| March 31, 2021 | 6.723B |
| December 31, 2020 | 6.432B |
| September 30, 2020 | 6.232B |
| June 30, 2020 | 6.134B |
| Date | Value |
|---|---|
| March 31, 2020 | 6.009B |
| December 31, 2019 | 5.843B |
| September 30, 2019 | 5.851B |
| June 30, 2019 | 5.742B |
| March 31, 2019 | 5.952B |
| December 31, 2018 | 6.137B |
| September 30, 2018 | 6.143B |
| June 30, 2018 | 6.276B |
| March 31, 2018 | 6.096B |
| December 31, 2017 | 5.778B |
| September 30, 2017 | 5.732B |
| June 30, 2017 | 5.660B |
| March 31, 2017 | 5.699B |
| December 31, 2016 | 5.640B |
| September 30, 2016 | 5.592B |
| June 30, 2016 | 5.370B |
| March 31, 2016 | 5.094B |
| December 31, 2015 | 5.187B |
| September 30, 2015 | 5.072B |
| June 30, 2015 | 4.979B |
| March 31, 2015 | 5.027B |
| December 31, 2014 | 4.722B |
| September 30, 2014 | 4.731B |
| June 30, 2014 | 4.714B |
| March 31, 2014 | 4.609B |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (TTM) Benchmarks
| AstraZeneca PLC | 10.40B |
| Johnson & Johnson | 21.04B |
| Eli Lilly & Co. | 26.71B |
| Merck & Co., Inc. | 3.169B |
| Novartis AG | 12.75B |